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Introduction: High Mobility Group Box Protein 1 (HMGB1) is a DNA-binding
protein that exerts inflammatory or pro-repair effects upon translocation from the
nucleus. We postulate aberrant HMGB1 expression in immune-mediated necrotising
myopathy (IMNM).
Methods: Herein, we compare HMGB1 expression (serological and sarcoplasmic) in
patients with IMNM with that of other myositis subtypes using immunohistochemistry
and ELISA.
Results: IMNM (n = 62) and inclusion body myositis (IBM, n = 14) patients had increased
sarcoplasmic HMGB1 compared with other myositis patients (n = 46). Sarcoplasmic
HMGB1 expression correlated with muscle weakness and histological myonecrosis,
inflammation, regeneration and autophagy. Serum HMGB1 levels were elevated in
patients with IMNM, dermatomyositis and polymositis, and those myositis patients with
extramuscular inflammatory features.
Discussion: Aberrant HMGB1 expression occurs in myositis patients and correlates
with weakness. A unique expression profile of elevated sarcoplasmic and serum HMGB1
was detected in IMNM.
Keywords: myositis, idiopathic inflammatory myopathy, HMGB1, immune-mediated necrotising myopathy,
immune-mediated necrotizing myopathy, inclusion body myositis, necrotising autoimmune myopathy, necrotizing
autoimmune myopathy
Abbreviations: ASAb, anti-synthetase antibodies (anti-Jo1, anti-OJ, anti-EJ, anti-PL7, anti-PL12); CK, creatinine
phosphokinase; DM, dermatomyositis; DrG, physician global visual analog scale (0 – 10); ELISA, enzyme-linked
immunosorbent assay; HAQ, Health Assessment Questionnaire (0 – 3); HMGB1, high mobility group box protein 1;
HMGCR, hydroxy-2-methyglutaryl-CoA reductase; HPF, high power field; IBM, inclusion body myositis; IFN, interferon;
IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; IMACS, International Myositis Assessment and Clinics
Studies Group; IMNM, immune mediated necrotising myopathy; IU/L, international units/liter; Jo1, anti-Jo1 antibody; LC3,
Microtubule-associated protein 1A/1B-light chain 3; MAA, myositis associated autoantibody; MDAAT-muscle, the muscle
activity component of the Myositis Disease Activity Assessment Tool (0 – 10); MDI, Myositis Damage Index (0 – 10); mg,
milligrams; MHC I, major histocompatibility complex I; MHCn, neonatal myosin heavy chain; MMT8, manual muscle testing
8 (0 – 80); MSA, myositis specific autoantibodies; N, number; NAM, necrotising autoimmune myopathy; NIMNM, non-
immune mediated necrotising myopathy; NSIIM, non-specific idiopathic inflammatory myopathy; PM, polymyositis; PNL,
prednisolone; PtG, Patient Global (0 – 10); Ro, anti-Ro52 antibody; RP, Raynaud’s phenomenon; SAMD, South Australian
Myositis Database; SRP, anti-signal recognition peptide antibody; UA, information unavailable; VAS, visual analog scale.
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INTRODUCTION
The idiopathic inflammatory myopathies (IIMs) are a group of
systemic autoimmune diseases characterized primarily by muscle
inflammation, but also potentially accompanied by a range of
extra-muscular manifestations. In adults, the term encompasses
dermatomyositis (DM), polymyositis (PM), inclusion body
myositis (IBM) and immune-mediated necrotising myopathy
(IMNM; also called necrotising autoimmune myopathy, NAM).
The etiology of these conditions remains obscure and the
pathogenic mechanisms likely differ between the subtypes, given
their distinct histopathological and immunological features.
Immune-mediated necrotising myopathy has been only relatively
recently described and the molecular mechanisms underlying
the immune attack on muscle are poorly understood (Allenbach
and Benveniste, 2013; Allenbach et al., 2018). It is becoming
increasingly apparent that a dysregulated innate immune system
contributes to the initiation and perpetuation of the IIMs, with
roles for type I interferon (IFN), toll-like receptors (TLRs),
various cytokines and the alarmin, High Mobility Group Box
Protein 1 (HMGB1), now well-established (Day et al., 2017).
HMGB1 is a ubiquitous non-histone nuclear DNA-binding
protein that can, under certain physiological and pathological
conditions, undergo extra-nuclear translocation where it may act
as a signal of tissue damage and a pro-inflammatory mediator
(Lotze and Tracey, 2005). In response to injurious stimuli,
inflammatory cells actively secrete HMGB1 in a controlled
manner, which requires post-translational modification of the
protein (Gardella et al., 2002; Lu et al., 2014). HMGB1 is also
rapidly passively released from necrotic cells, following nuclear
membrane breakdown (Scaffidi et al., 2002). This protein is
implicated in a broad range of conditions, including sepsis,
malignancy and autoimmune diseases (Harris and Raucci, 2006;
Diener et al., 2013; Magna and Pisetsky, 2014). With regards to
IIM, extra-nuclear HMGB1 expression has been demonstrated
in the muscle of mice with experimental autoimmune myositis
(Wang and Qin, 2016) and in muscle from IBM (Muth et al.,
2015), PM, and DM (Ulfgren et al., 2004; Grundtman et al.,
2010) patients. HMGB1 positive fibers in PM and DM muscle
are non-necrotic, suggesting active release of HMGB1 from the
muscle cell nucleus (Ulfgren et al., 2004). Of note, sarcoplasmic
HMGB1 expression in IIM patients has not been confirmed in
all reports (Cseri et al., 2015). Patients with new-onset DM and
PM have elevated serum HMGB1, and these levels correlate with
survival and the presence of interstitial lung disease (ILD) (Shu
et al., 2016). In addition to descriptive research, a pathogenic
role for HMGB1 in muscle is suggested by experimental studies.
For instance, myocytes or myofibres exposed to recombinant
HMGB1 demonstrate intracellular protein aggregation, increased
cell death (Muth et al., 2015), aberrant MHC-I expression
(Grundtman et al., 2010; Muth et al., 2015) and impaired calcium
release during repeated tetanic stimulation, suggesting enhanced
muscle fatigue (Grundtman et al., 2010; Zong et al., 2013).
However, HMGB1 is a multifaceted protein that exerts
different effects depending on its redox state, the presence
of post-translational modifications, the complexes it forms
with other stimulatory or inhibitory proteins and the cellular
receptor through which it ultimately signals. HMGB1 has been
shown to induce muscle regeneration in mouse models of
ischaemic myopathy (De Mori et al., 2007) and a non-oxidisable
mutant form of exogenous HMGB1 promotes muscle and liver
regeneration in mice via interaction with the CXCR4 receptor
(Tirone et al., 2018). Cytosolic HMGB1 is a crucial regulator
of autophagic responses to cellular stress, where autophagy is a
beneficial physiological process enabling cellular proteins to be
degraded and recycled (Tang et al., 2010). Within IIM muscle,
HMGB1 co-localizes marker of autophagy (Cappelletti et al.,
2014). As such, while HMGB1 appears to play a role in IIM
pathophysiology and may have direct negative effects on muscle
function, it may paradoxically aid in muscle restoration. The
role of HMGB1 in IIM appears complex and clearly warrants
further investigation. Moreover, research evaluating expression
of this protein in IIM has focused on DM, PM and IBM
and these discoveries may not be readily extrapolated to the
condition of IMNM.
Herein we compare expression of HMGB1 in IMNM patients
with that of other IIM patients. We correlate these findings with
clinical, histopathological and serological parameters. To our
knowledge, this is the largest cohort study evaluating HMGB1
in IIM and the first to describe sarcoplasmic and serum levels
of HMGB1 in IMNM.
MATERIALS AND METHODS
Subjects
Muscle tissue, serum and clinical data were obtained from
the South Australian Myositis Database (SAMD), a registry of
patients with PM, DM, IBM, non-specific IIM (NSIIM) and
‘necrotising myopathy.’ Recruitment to the SAMD is based
on histological criteria which have previously been described
for PM, DM, and IBM (Limaye et al., 2013). All cases of
PM, DM and IBM adhered to published classification criteria
(Hoogendijk et al., 2004; Rose and Group, 2013). Cases are
recorded as ‘necrotising myopathy’ if there is myofibre necrosis
and an absence of histological features consistent with other
neuromuscular conditions. This was considered to be immune-
mediated if the treating clinician documented a diagnosis of
IMNM or NAM. Cases of NSIIM have muscle inflammation
with insufficient biopsy criteria to allow subclassification (e.g.,
scattered perimysial or endomysial inflammation that does
not surround or invade myofibres). Muscle from 62 patients
diagnosed with IMNM between 2001 and 2016, was included.
Forty-five patients with a diagnosis of DM, PM, or IBM were
included for comparison in addition to 15 patients with NSIIM
and 17 controls. Control muscle constituted biopsies obtained
from subjects with diffuse myalgia, weakness or unexplained
creatine phosphokinase (CK) elevations, but which lacked any
myopathic features. Control serum samples were collected from
healthy volunteers. Some cases were excluded from this study due
to lack of clinical information, alternative diagnosis or technical
difficulties (Supplementary Figure 1).
Clinical information was prospectively recorded. This
included data regarding the presence of weakness, dysphagia,
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 April 2020 | Volume 8 | Article 226
fcell-08-00226 April 15, 2020 Time: 18:42 # 3
Day et al. HMGB1 Expression in Myositis
extramuscular features and exposure to medications such as
statins. As part of standard clinical assessment, most patients
were tested for the following myositis-specific and myositis-
associated antibodies (MSAs, MAAs; Euroline Myositis Profile
3): anti-signal recognition peptide (SRP), anti-histidyl-tRNA
synthetase (Jo1), anti-threonyl-tRNA synthetase (PL7), anti-
alanyl-tRNA synthetase (PL12), anti-glycyl-tRNA synthetase
(EJ), anti-isoleucyl-tRNA synthetase (OJ), anti-Mi2, anti-Ro52,
anti-Ku, anti-PMSCl75 and anti-U1RNP. A subset were analyzed
for anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)
antibodies (ELISA, PathWest). Disease activity and damage
were assessed in a number of patients using the following:
(1) Manual Muscle Testing 8 (MMT8), (2) Patient and physician
global assessments by visual analog scale (VAS; PtG and DrG
respectively), (3) Health Assessment Questionnaire (HAQ)
Disability Index, (4) the muscle activity component of the
Myositis Disease Activity Assessment Tool by VAS (MDAAT-
muscle), (5) CK and (6) clinician assessment of muscle damage by
VAS (Myositis Damage Index; MDI). The date of symptom onset
and the degree of corticosteroid exposure at biopsy were collected
retrospectively. This study was approved by the Central Adelaide
Local Health Network Ethics Committee and the University of
South Australia Human Research Ethics Committee.
Muscle Biopsy
Muscle samples were obtained via open surgical biopsy or
needle biopsy. Specimens were placed into transverse orientation,
mounted on cork, frozen in isopentane cooled using liquid
nitrogen (Cash and Blumbergs, 1994) and stored in liquid
nitrogen until sectioning. Consecutive 9 µm-thick cryostat
muscle sections were placed on coated slides. H&E staining was
performed on the first and last sections of each series. Sections
intended for MHC I, MHCn, CD68, CD45 and LC3 staining were
air dried for 30 min then stored at−80◦C until use (1 – 68 days).
Sections intended for HMGB1 staining were air dried for 30 min,
fixed for 10 min in 10% neutral buffered formalin, air dried for
30 min then stored at −80◦C until use (1 – 33 days). On the
day of staining, antigen retrieval was achieved on slides intended
for HMGB1 staining by immersion in sodium citrate buffer
(pH 6.0) followed by heat induced epitope retrieval utilizing
microwave treatment.
Immunohistochemistry
Immunohistochemistry was performed using an autostainer.
Slides were washed in buffer (TA-999-TT, Thermo Scientific),
blocked for 5 min with 2% H2O2 in methanol, washed again
with buffer then incubated for 5 min with a commercial blocking
agent (TA-060-PBQ, Thermo Scientific). After a further wash
with buffer, slides were incubated with primary antibody at
room temperature for 30 min. Primary antibodies used were
anti-HMGB1 at 1/300 (ab18256, Abcam), anti-MHC I at 1/2000
(M0736, Dako), anti-CD45 at 1/400 (M0701, Dako), anti-
CD68 at 1/8000 (M0814, Dako), anti-CD8 at 1/75 (M7103,
Dako), anti-LC3 at 1/50 (AM1800a, Abgent), anti-neonatal
myosin heavy chain (MHCn) at 1/100 (NCL-MHCn). Antibodies
were diluted in commercial antibody diluent (TA-125-ADQ,
Thermo Scientific). Slides were then washed, incubated in
commercial primary antibody enhancer (TL-060-PB, Thermo
Scientific) for 10 min, washed and incubated with a commercial
detection system comprising a universal secondary antibody
formulation with anti-Mouse IgG and anti-Rabbit IgG specificity,
conjugated to horse-radish-peroxidase polymer (TL-060-PH,
Thermo Scientific) for 15 min. After washing in buffer, slides
were incubated with peroxidase-compatible liquid substrate
chromagen system (Dako K3468) for 10 min, followed by
haematoxylin counterstaining.
Positive controls were performed for each antibody in every
staining procedure. A negative control was performed by
omitting primary antibody in every staining procedure, both
for an unfixed slide and a formalin-fixed microwave-retrieved
slide. For ten cases, a formalin-fixed, antigen-retrieved section
underwent staining with a rabbit IgG isotype control (Invitrogen,
31235), at the same concentration as the HMGB1 antibody.
Lymphoid tissue was used to confirm HMGB1 staining in non-
muscle tissue.
Modified Gomori Trichrome Staining
Consecutive 9 µm-thick cryostat sections of unfixed fresh frozen
IBM muscle, normal muscle and a positive “ragged red” control
were stained with Harris’ haematoxylin for 30 min, washed
then stained with modified Gomori trichrome stain (laboratory-
prepared, pH 3.4) for 15 min followed by differentiation with
0.2% aqueous acetic acid.
Quantification of Immunohistochemical
Staining
Slides were graded using traditional microscopy for HMGB1,
MHC I, LC3 and MHCn staining in a semi-quantitative manner
by a muscle pathologist (SO) (Supplementary Table 1). The H&E
stained sections were graded for degree of necrosis by the same
pathologist, where necrosis was defined as muscle cells exhibiting
a combination of the following features: swelling, hyalinization,
hypereosinophilia, pallor, myophagocytosis. Slides were graded
by twice on separate occasions; median grades are reported.
A second trained investigator (JD) validated the grading scale
by manually counting positive and negative myofibres in 10
randomly selected high power fields (HPFs, magnification× 400)
and calculating the percentage of HMGB1+ fibers. Manual cell
counts of CD45+ leucocytes and CD68+ macrophages were
also performed. Evaluation of each histological parameter was
completed for the entire cohort before proceeding to the next
parameter. At the time of histological evaluation, investigators
were blinded to the clinical details and the grades assigned to
other immunoproteins.
Serum Collection and Analysis
A commercial ELISA kit was used to measure serum
concentrations of HMGB1 (Cloud-Clone Corporation, Texas,
United States). Each sample was diluted 1/100 in phosphate
buffered saline and tested in duplicate. One sample was re-tested
on each ELISA plate.
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Statistics
Statistical analysis was performed using STATA version 14.0.
Values were expressed as the median and the interquartile
range (IQR). Two group comparisons were performed using
the Mann–Whitney U test. When three or more groups were
compared, a Kruskal–Wallis H test was conducted to identify
whether a statistically significant difference existed, followed by
a post hoc Dunn’s test. A Bonferroni correction was applied for
multiple comparisons. Fisher’s exact test was used to analyze
categorical data. Spearman correlations were performed to
analyze associations between radiological grades and continuous
or ordinal parameters. Number of cases analyzed are indicated





Intra-rater reliability was high (κ > 0.70) for all histological
parameters. The average percentage of HMGB1+ myofibres
correlated strongly with grades assigned by the muscle
pathologist (rs 0.83, p < 0.01).
Subject Characteristics
Subjects Undergoing Immunohistochemical Analyses
Clinical characteristics of subjects are presented in Table 1.
Fifty-eight patients had both serum and muscle tissue available
for analysis. DM patients were more likely to have received
corticosteroids at the time of biopsy (p = 0.002); this may
reflect more frequent occurrence of extramuscular IIM features
in this subgroup. Serum from IIM patients was collected within
139 days (56–695 days) of the muscle biopsy and most (71%;
40/56) were on immunotherapy at the time of venepuncture.
Compared with other IIM subsets, patients with PM or DM were
more likely to exhibit extramuscular manifestations such as rash
(p< 0.001), Raynaud’s phenomenon (RP, p< 0.01), inflammatory
joint disease (p = 0.03), ILD (p = 0.02) and to be MAA-positive
(p = 0.01). Fifty percent (56/113) of the pooled serum and IHC
cohort were MSA+ and/or MAA+, and a variety of antibodies
were represented (Supplementary Table 2). Presence of anti-
Ro52 was most common (n = 23), followed by anti-HMGCR
(n = 10), anti-PL7 (n = 7), anti-Mi-2 (n = 5), anti-Jo1 (Jo1+,
n = 5), anti-SRP (SRP+, n = 5), anti U1RNP (n = 3), anti-
PL-12 (n = 3), anti-PMSCL75 (n = 3), anti-PMSCl100 (n = 2),
anti-Ku (n = 1), and anti-OJ (n = 1). Two IMNM patients were
anti-Mi2+ but had myonecrosis on biopsy and lacked clinical
features or histopathology consistent with DM. One patient
was anti-HMGCR+, but had minor necrosis and inflammatory
histopathology consistent with PM.
Sarcoplasmic HMGB1 levels are elevated in muscle from IIM
patients but levels differ according to disease subtype
HMGB1 sarcoplasmic immunostaining was low grade and
stippled in histologically normal control muscle (Figure 1A) and
comparatively strong in IIM patients (Figure 1B). As expected,
muscle nuclei and infiltrating immune cells were strongly
HMGB1 positive (e.g., Figure 1B). Sarcoplasmic expression was
highest in IMNM followed by IBM and PM (Figure 2). Both
IBM and IMNM patients exhibited significantly elevated levels of
sarcoplasmic staining compared to those with DM and NSIIM.
Sarcoplasmic HMGB1 expression correlates with
multifactorial processes in IIM
Sarcoplasmic HMGB1 grades correlated strongly (rs 0.62 –
0.77, p < 0.01) with the degree of muscle cell necrosis for
all IIM subtypes except NSIIM, suggesting that necrosis is an
important driver of sarcoplasmic HMGB1 staining even in those
subtypes where this is not the dominant histological feature. Both
macrophage and CD45+ leucocyte infiltration were strongly
associated with sarcoplasmic HMGB1 expression (rs 0.63, 0.61,
p < 0.001), although these correlations were less robust and
not significant for IBM patients. In fact, for IBM patients, the
degree of MHCn+ (regenerating) fibers (rs 0.77, p < 0.001)
and LC3+ staining (rs 0.75, p < 0.001) correlated most strongly
with HMGB1 expression. On a cellular level, these processes co-
localized within individual muscle fibers. Many necrotic cells
exhibited strong positive staining for HMGB1 (Figures 3A,B).
Regenerating fibers were frequently present in IIM muscle and
always stained positively for HMGB1 (Figures 3C,D). In IBM,
abnormal HMGB1 staining was visualized in fibers exhibiting
features of abnormal cytoplasmic protein inclusions, vacuolar
change and autophagic protein accumulation (Figures 3E–H).
Isotype control staining was negative (Supplementary Figure 2).
Only occasionally was HMGB1 positivity noted in relatively
normal appearing mature myofibres. This typically occurred
in areas of inflammation and might reflect active secretion
of HMGB1 by activated myofibres. Analysis of sarcoplasmic
HMGB1 levels by individual autoantibodies was limited by small
numbers. Sarcoplasmic HMGB1 levels were high in all anti-SRP+
IMNM patients (Grade ≥ 2, n = 5) whereas a range of staining
patterns were observed in anti-Ro+ IIM, antisynthetase+ IIM
and anti-HMGCR+ IIM.
Reduced sarcoplasmic HMGB1 staining in some IIM patients
may reflect corticosteroid exposure
We found a modest negative correlation between cumulative
corticosteroid dose and sarcoplasmic HMGB1 expression
(rs −0.30, p < 0.01). Patients with inflammatory arthritis
had lower muscular HMGB1 staining than those without
arthritis (p < 0.05). These patients also had higher cumulative
prednisolone exposure (325 mg vs. 0 mg, p = 0.04), which
may explain the comparatively reduced sarcoplasmic
HMGB1 expression.
Sarcoplasmic HMGB1 correlates with muscle weakness
Twenty-four IIM patients had MMT8 assessments at the time
of muscle biopsy and there was a strong negative correlation
between strength and sarcoplasmic HMGB1 levels. This was true
for IMNM (rs −0.57, p = 0.03, n = 14) and non-IMNM IIM
patients (rs −0.75, p = 0.01, n = 19). Sarcoplasmic HMGB1
expression consistently correlated with every bedside clinical
disease activity index tested (Figure 4). There was a modest
correlation with serum CK level (rs 0.31, p < 0.01, n = 95). There
were no correlations between HMGB1 grades and indices of
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TABLE 1 | Subject characteristics.
IMNM DM PM IBM NSIIM Controls
Subjects Undergoing Histological Analysis
N 62 18 13 14 15 17
Age (years)a 64 (57 – 69) 55 (47 – 70) 60 (45 – 66) 68 (64 – 79) 59 (47 – 69) 45 (26 – 51)
Female 32 (51%) 12 (67%) 7 (54%) 7 (50%) 10 (67%) 10 (59%)
Symptom Duration (Days) a 47 104 136 1275 UA
(22 – 176) (88 – 274) (122 – 244) (1096 – 2718) 92 (75 – 130)
n = 50 n = 8 n = 9 n = 9 n = 5
MSA positivity 18/44 (41%) 5/16 (31%) 3/13 (23%) 2/12 (17%) 2/12 (17%) UA
MAA positivity 4/44 (9%) 8/17 (47%) 6/13 (46%) 2/12 (17%) 3/13 (23%) UA
EM featureb 10/58 (17%) 17 (94%) 7 (54%) 5 (36%) 9/14 (64%) NA
PNL dose (mg)a 0 (0 – 0) 20 (0 – 55) 0 (0 – 7) 0 (0 – 0) 0 (0 – 0) 0 (0 – 0)
n = 48 n = 12 n = 9 n = 13 n = 14 n = 15
Cumulative PNL dose (mg)a 0 840 0 0 105 UA
(0 – 0) (150 – 2625) (0 – 370) (0 – 0) (0 – 350)
n = 35 n = 12 n = 8 n = 13 n = 9
Peak CK (IU/L) 4086 546 2237 470 400 164
(1467 – 10799) (248 – 1942) (897 – 3193) (217 – 709) (73 – 839) (92 – 673)
MMT8c 76 (64 – 80) 70 (62 – 80) 74 (64 – 80) 64 (54 – 74) 80 (78 – 80) NA
n = 23 n = 7 n = 7 n = 8 n = 5
Subjects Undergoing Serological Analysis
N 34 14 10 13 5 50
Age (years)d 65 (57 – 70) 67 (48 – 75) 60 (52 – 72) 67 (67 – 78) 69 (69 – 70) 45 (29 –56)
Female 15 (44%) 8 (57%) 8 (80%) 7 (54%) 4 (80%) 20 (40%)
Days since biopsyd 185 93 141 119 190 UA
(51 – 1687) (54 – 677) (85 – 805) (59 – 181) (0 – 334)
MSA positivity 7/24 (29%) 4/12 (33%) 2/10 (20%) 1/10 (10%) 1/4 (25%) UA
MAA positivity 3/24 (13%) 7/13 (54%) 4/10 (40%) 3/10 (30%) 1 (20%) UA
Cumulative PNL dose (mg)d 3250 2080 0 0 0 UA
(0 – 5875) (300 – 4700) (0 – 8340) (0 – 4050) (0 – 350)
n = 24 n = 6 n = 7 n = 11 n = 3
EM featureb 6/32 (19%) 12/13 (92%) 6/10 (60%) 3/13 (23%) 2/5 (40%) UA
IIM rash 1/30 (3%) 10/13 (77%) 1/9 (11%) 0/12 (0%) 1/5 (20%) UA
RP 1/32 (3%) 3/13 (23%) 5/10 (50%) 2/13 (15%) 1/5 (20%) UA
ILD 1/33 (3%) 3/11 (27%) 2/10 (20%) 1/13 (8%) 0/5 (0%) UA
Inflammatory joint disease 5/32 (16%) 5/13 (38%) 4/10 (40%) 1/13 (8%) 2/5 (40%) UA
Myalgia 19/32 (59%) 5/12 (42%) 4/10 (40%) 4/12 (33%) 2/5 (40%) UA
aAt the time of muscle biopsy. bExtramuscular feature: IIM related rash (Heliotrope rash, Gottron’s papules, Gottron’s sign, shawl sign or mechanic’s hands), inflammatory
joint disease (polyarthralgia and/or synovitis), ILD or RP. cFirst recorded assessment post diagnostic biopsy. dAt the time of serum collection. CK, creatinine phosphokinase;
DM, dermatomyositis; IBM, inclusion body myositis; IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; IMNM, immune mediated necrotising myopathy;
IU/L, international units per liter; MAA, myositis associated autoantibody; mg, milligrams; MMT8, manual muscle test 8 (0 – 80); MSA, myositis specific autoantibodies;
N, number; NSIIM, non-specific idiopathic inflammatory myopathy; PM, polymyositis; PNL, prednisolone; RP, Raynaud’s phenomenon; UA, information unavailable.
disease-related damage (MDI scores) or patient disability (HAQ
scores). Sarcoplasmic HMGB1 expression modestly negatively
correlated with symptom duration in IMNM patients (rs −0.38,
p < 0.01, n = 50) but trended toward a positive correlation
in IBM patients (rs 0.62, p = 0.07, n = 9), likely reflecting
that different processes are responsible for HMGB1 expression
in these diseases.
Serum HMGB1 levels are elevated in patients with PM, DM,
and IMNM
Serum HMGB1 was elevated in IIM compared with healthy
controls (p < 0.001), however, levels varied markedly by IIM
subtype (Figure 5A). As such, patterns of serum HMGB1
expression differed from that observed within muscle. For
instance, despite exhibiting notable sarcoplasmic staining,
circulating levels of HMGB1 in IBM patients did not differ from
controls. Conversely, high serum HMGB1 was detected in DM
patients despite these patients exhibiting low sarcoplasmic levels.
Patients with IMNM had notably high intramuscular and high
serum HMGB1 levels.
There were no significant differences in serum HMGB1
levels between IIM patients who had serum collected early
in the disease process (within 6 months of diagnosis) and
those whose serum collection was more delayed (Figure 5B).
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FIGURE 1 | Staining for High Mobility Group Box Protein 1 (HMGB1) in control and IIM muscle. (A) Muscle tissue from a control subject demonstrating lightly stippled
sarcoplasmic HMGB1 staining and strong positive staining of muscle nuclei. This case was assigned HMGB1 grade zero. (B) Muscle tissue from a patient with
seronegative MHC I + NM demonstrating positive staining of numerous muscle fibers, muscle cell nuclei and inflammatory cells. This case was assigned HMGB1
grade 3. Magnification: x 200. IIM, idiopathic inflammatory myopathy; IMNM, immune-mediated necrotising myopathy; MHC I, major histocompatibility complex I.
FIGURE 2 | Sarcoplasmic expression of HMGB1 by IIM subtype. Expression levels by (A) Grading scales and (B) Percentage of positive fibers per high power field.
**p < 0.001 versus controls. *p < 0.05 versus controls. DM, dermatomyositis; HMGB1, high mobility group box protein 1; IBM, inclusion body myositis; IIM,
idiopathic inflammatory myopathy; IMNM, immune-mediated necrotising myopathy; NSIIM, non-specific idiopathic inflammatory myopathy, PM, polymyositis.
There was no correlation between serum HMGB1 levels in
IIM patients and symptom duration. Sarcoplasmic and serum
levels of HMGB1 did not correlate in the 58 patients with
both samples available, possibly owing to the multifactorial
nature of intramuscular HMGB1 expression and because
these samples were collected at different time-points of the
disease trajectory.
Extramuscular features are associated with elevated serum
HMGB1 levels
High serum HMGB1 levels were observed in IIM patients with
RP, ILD and inflammatory joint disease (Table 2). Myalgia was
common and was also associated with significantly elevated
serum HMGB1. Myalgic patients also had more polyarthralgia
(10/33, 30% versus 4/36, 11%, p = 0.046) compared with non-
myalgic IIM patients, but did not exhibit higher serum CK,
myonecrosis or muscle inflammation. Together this suggests that
myalgia may be systemically driven or reflect joint inflammation,
rather than intramuscular pathology per se.
Patients with anti-Ro52+ antibodies had significantly elevated
serum HMGB1 levels (Table 2). We did not observe any
association between circulating HMGB1 levels and muscle
disease activity measures, antisynthetase antibodies or the
presence of cancer.
DISCUSSION
Understanding the molecular events underpinning IIM
pathophysiology and how this differs between subtypes
is critical in the pursuit of developing targeted therapies,
which is increasingly the goal in rheumatological practice.
Herein we evaluated expression of HMGB1 in all forms of
IIM, including subtypes in which levels of expression of
this protein have been hitherto unknown, such as IMNM
and NSIIM. Structures demonstrating HMGB1 expression
included infiltrating immune cells, necrotic myofibres and
those exhibiting regeneration, autophagy and mitochondrial
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FIGURE 3 | Continued
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 April 2020 | Volume 8 | Article 226
fcell-08-00226 April 15, 2020 Time: 18:42 # 8
Day et al. HMGB1 Expression in Myositis
FIGURE 3 | Relationships between High Mobility Group Box Protein 1 (HMGB1) and other histopathological processes in the muscle. (A) H&E stain of muscle from a
patient with IMNM demonstrating scattered necrotic fibers (examples *). These fibers stain positively for HMGB1 (B). Scale bars 100 microns. (C) Neonatal myosin
heavy chain (MHCn) staining of a section obtained from a patient with IMNM demonstrating numerous regenerating fibers (examples *). These fibers exhibit strong
HMGB1 staining (D). Scale bars 50 microns. (E) LC3 staining of muscle from a patient with IBM showing abnormal positivity in two cells (*). These cells were positive
for HMGB1 (F). (G) Modified Gomori trichrome stain of a patient with IBM demonstrating two cells with abnormal cytoplasmic protein inclusions and vacuolar
change. These cells were HMGB1 positive (H). Scale bars 50 microns. Magnification: (A,B) x200; (C–F) x400; (G,H) x 600. HMGB1, high mobility group box protein
1; IMNM, immune-mediated necrotising myopathy; LC3, Microtubule-associated protein 1A/1B-light chain 3.
FIGURE 4 | Relationship between bedside disease activity measures and sarcoplasmic HMGB1 grades in IIM patients. Graphs plot HMGB1 grades according to:
(A) Manual Muscle Testing 8 scores (MMT8, 0–80). (B) The muscle activity component of the Myositis Disease Activity Assessment Tool by visual analog scale
(MDAAT-muscle VAS, 0 – 10). (C) Doctor Global assessment of disease activity by VAS (0 – 10). (D) Patient Global assessment of disease activity by VAS (0 – 10).
dysfunction. We additionally observed strong HMGB1 staining
in all muscle nuclei and low-grade staining in our histologically
normal controls. Given small amounts of HMGB1 are present
cytosol under normal cellular conditions (Kuehl et al., 1984;
Tang et al., 2010), the sarcoplasmic HMGB1 observed in our
control tissue is likely physiological. As such, we have shown
HMGB1 to be associated with multiple processes in the muscle
microenvironment ranging from physiological to pathological,
damaging to restorative. The relative balance and temporal
evolution of these processes may explain the varying degrees
of HMGB1 expression we observed across IIM subtypes. While
it seems paradoxical that one protein could be associated
with multiple processes, it is in keeping with the complex
functional properties of HMGB1. The biological actions of
HMGB1 are strikingly diverse and evolve over time owing to
its unique biochemistry, its ability to undergo post-translation
modifications, complex with other proteins and signal through
a multitude of receptors. As others have emphasized (Magna
and Pisetsky, 2014), HMGB1 should be conceptualized as an
ensemble of proteins rather than a single species and with a fixed
structure or function.
Overall, our data imply a deleterious role for HMGB1 in
IIM, as sarcoplasmic expression to correlated with clinical
disease activity and histological inflammation and necrosis.
This is consistent with evidence demonstrating HMGB1
to have pro-inflammatory properties and correlate with
inflammatory disease activity. In addition to cytokine and
chemokine properties, HMGB1 can activate the classical
pathway of complement (Kim et al., 2018), where complement
deposition is a key mediator of myonecrosis (Engel and
Biesecker, 1982). It is conceivable that HMGB1 released
from necrotic myofibres could trigger further local muscle
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FIGURE 5 | Serum levels of HMGB1 in patients with IIM. (A) Serum levels of HMGB1 by IIM subtype. (B) Serum levels in IIM patients with early (<6 months since
diagnostic biopsy) and late (>6 months since diagnostic biopsy) disease.
cytolysis and perpetuate further damage in a self-sustaining
process. Therapeutic blockade of HMGB1 in inflammatory
disease states in is under consideration and been evaluated in
experimental models of drug-induced liver injury (Lundback
et al., 2016) and inflammatory arthritis (Kokkola et al., 2003),
with promising results.
However, data herein and elsewhere links HMGB1 with
ostensibly beneficial processes such as myofibre regeneration
TABLE 2 | Serum HMGB1 levels according to the presence of certain clinical
features.
Clinical feature Feature present Feature absent p-value


















































IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; Ro52, anti-
Ro52 antibodies.
(De Mori et al., 2007; Tirone et al., 2018) and metabolic
functions such as autophagy (Muth et al., 2015; Tang et al.,
2010). Accelerated tissue regeneration is observed following
administration of recombinant HMGB1 in mouse models of
muscle injury (De Mori et al., 2007). This myoregenerative
effect is particularly pronounced when HMGB1 is administered
in a fully reduced isoform (Tirone et al., 2018). As such,
promoting certain HMGB1 pathways therapeutically might
accelerate tissue repair in various clinical scenarios. Development
of therapeutics that specifically inhibit isoforms of HMGB1
contributing to inflammatory pathology or promote those
isoforms involved in reparative processes would clearly be the
most desirable strategy. Of note, regenerating myofibres have
been implicated in the elaborate pathophysiological mechanisms
that underpin IIM (Tournadre and Miossec, 2013), and attempts
to enhance myoregeneration with exogenous HMGB1 may not
be prudent in these diseases. Further research evaluating the
role of specific HMGB1 isoforms in IIM and the role of
regenerating myofibres in disease perpetuation is clearly required
before therapeutic intervention exploiting HMGB1 pathways can
be considered.
We observed elevated serum HMGB1 levels in IMNM,
PM and DM patients, however, the source of circulating
HMGB1 may differ between subtypes. In IMNM, this
likely reflects rapid, passive release of HMGB1 into the
extracellular space due to myonecrosis. Indeed, HMGB1
has been used as a marker of necrosis in experimental
studies of tumor pathophysiology (Jeon et al., 2013; Kang
et al., 2014). However, HMGB1 can also be released from
activated immune cells present in inflamed tissues; this
may explain the association between HMGB1 levels in
serum and the presence of extra-muscular autoimmune
manifestations, such as RP, joint disease and ILD. Previous
studies have demonstrated elevated HMGB1 in the serum
and/or broncho-alveolar fluid of IIM-related ILD and other
inflammatory fibrotic lung conditions (Ebina et al., 2011;
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Shu et al., 2016; Ying et al., 2017; Shimizu et al., 2018). These
results support a clinical role for measuring serum HMGB1
levels; this could supplement muscle biopsy in the subtyping
of IIM and, potentially, screening for IIM-related ILD (Shu
et al., 2016). Our findings suggest that this assessment will
have discriminatory utility even in patients with well-established
disease who are receiving immunomodulatory therapy, although
further studies evaluating the sensitivity and validity of this
minimally invasive test are required. Importantly, HMGB1
that is actively secreted by inflammatory cells undergoes
critical post-translational modifications (acetylation) of ‘nuclear
localization sites’ (NLSs) contained within the protein in order
to exit the nucleus (Lotze and Tracey, 2005). Conversely,
passive release does not involve NLS modification and thus
necrotic cells do not generate hyperacetylated HMGB1 (Yang
et al., 2015). An assay that differentiates these HMGB1
isoforms could allow clinicians to quantify the degrees of
necrosis versus inflammation in individual patients, and could
conceivably aid in IIM subtyping. The oxidation state of HMGB1
also differs according to the mechanism of cellular release
but, considering this can rapidly alter in the extracellular
milieu (Venereau et al., 2012), assays determining the degree
of NLS acetylation may have more discriminatory value.
Unfortunately, HMGB1 isoform analysis is challenging, requires
high-end mass spectrometry instrumentation and is currently
successfully performed by only one research group worldwide
on a collaborative basis (Yang et al., 2012). Development
of further reliable isoform assays would advance scientific
understanding regarding the role of HMGB1 isoforms in
disease pathogenesis, information vital for clinical translation of
therapeutics targeting HMGB1.
This study has several limitations. It is descriptive in nature
and the complex mechanisms underpinning the associations
we have observed cannot be determined. We did not perform
HMGB1 receptor staining or have access to HMGB1 isoform
analysis, which would have provided added insights. Our sample
size was small, owing to the rare nature of these disorders.
However, this is a large study evaluating HMGB1 expression in
IIM and the first to describe elevated levels in the muscle and
serum of IMNM patients. These important findings may inform
future critical mechanistic studies regarding the role of HMGB1
in autoimmune muscle disorders.
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